Title: A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index
Version: 1 Date: 10 Jul 2023
Reviewer's report:
A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index Running Head: Impact of erector spine
mass on the prognosis of HBV-ACLF. This is an interesting study, but there are limitations in
the analysis. My comments are as follows:
1. Write details of inclusion and criteria in the methods section
2. How many patients had HCC at baseline?
3. What was the basis of taking the ESI cut-off 12.05 in the present study?
4. How were patients with HBV-ACLF managed? What was their drug compliance?
5. What fraction of patients were on antiviral drugs before the onset of ACLF?
6. What were the acute precipitants in this cohort of patients?
7. What fraction of patients had diabetes? Was diabetes adjusted in the analysis?
8. What were the causes of mortality?
9. A very high proportion of patients had in-hospital infections. What were the sites of infections?
How were the infections managed? Was a higher infection rate (MDR organisms) responsible
for deaths? What were the differences in the drug-resistant organisms between the 2 groups?
10. At baseline, what were the infection rates between the 2 groups?
11. Write details of tests used for the correlation of ESI with SMI in the statistical analysis section
12. Table 3 needs to provide details of all mortality-related factors. It is unclear why mortality
is shown in a row and what it predicts. Take a statistician's help to present the factors associated
with mortality.
Title: A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index
Version: 1 Date: 10 Jul 2023
Reviewer's report:
A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index Running Head: Impact of erector spine
mass on the prognosis of HBV-ACLF. This is an interesting study, but there are limitations in
the analysis. My comments are as follows:
1. Write details of inclusion and criteria in the methods section
2. How many patients had HCC at baseline?
3. What was the basis of taking the ESI cut-off 12.05 in the present study?
4. How were patients with HBV-ACLF managed? What was their drug compliance?
5. What fraction of patients were on antiviral drugs before the onset of ACLF?
6. What were the acute precipitants in this cohort of patients?
7. What fraction of patients had diabetes? Was diabetes adjusted in the analysis?
8. What were the causes of mortality?
9. A very high proportion of patients had in-hospital infections. What were the sites of infections?
How were the infections managed? Was a higher infection rate (MDR organisms) responsible
for deaths? What were the differences in the drug-resistant organisms between the 2 groups?
10. At baseline, what were the infection rates between the 2 groups?
11. Write details of tests used for the correlation of ESI with SMI in the statistical analysis section
12. Table 3 needs to provide details of all mortality-related factors. It is unclear why mortality
is shown in a row and what it predicts. Take a statistician's help to present the factors associated
with mortality.
Please review this paper.
user
Title: A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index
Version: 1 Date: 10 Jul 2023
Reviewer's report:
A novel imaging index for predicting adverse progression in acute-on-chronic liver failure
related to hepatitis B virus: the low erector spine index Running Head: Impact of erector spine
mass on the prognosis of HBV-ACLF. This is an interesting study, but there are limitations in
the analysis. My comments are as follows:
1. Write details of inclusion and criteria in the methods section
2. How many patients had HCC at baseline?
3. What was the basis of taking the ESI cut-off 12.05 in the present study?
4. How were patients with HBV-ACLF managed? What was their drug compliance?
5. What fraction of patients were on antiviral drugs before the onset of ACLF?
6. What were the acute precipitants in this cohort of patients?
7. What fraction of patients had diabetes? Was diabetes adjusted in the analysis?
8. What were the causes of mortality?
9. A very high proportion of patients had in-hospital infections. What were the sites of infections?
How were the infections managed? Was a higher infection rate (MDR organisms) responsible
for deaths? What were the differences in the drug-resistant organisms between the 2 groups?
10. At baseline, what were the infection rates between the 2 groups?
11. Write details of tests used for the correlation of ESI with SMI in the statistical analysis section
12. Table 3 needs to provide details of all mortality-related factors. It is unclear why mortality
is shown in a row and what it predicts. Take a statistician's help to present the factors associated
with mortality.
assistant